China Biologic Products Inc. (NASDAQ:CBPO)’s share price dropped 2.9% during trading on Monday . The company traded as low as $127.73 and last traded at $130.22, with a volume of 159,217 shares. The stock had previously closed at $134.17.

CBPO has been the topic of a number of recent research reports. Jefferies Group reaffirmed a “buy” rating and issued a $136.00 target price on shares of China Biologic Products in a report on Friday, July 22nd. Zacks Investment Research raised China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday, July 5th.

The firm has a market cap of $3.39 billion and a price-to-earnings ratio of 36.61. The company’s 50 day moving average price is $112.46 and its 200-day moving average price is $115.61.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.10. During the same period in the previous year, the company posted $1.06 earnings per share. The business had revenue of $91.40 million for the quarter, compared to analyst estimates of $87.60 million. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. Equities analysts predict that China Biologic Products Inc. will post $4.29 EPS for the current year.

In other news, Director Wp X. Biologics Llc sold 2,775,000 shares of the business’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total transaction of $308,025,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Ming Yin sold 19,618 shares of the business’s stock in a transaction on Friday, May 20th. The shares were sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the sale, the vice president now directly owns 51,419 shares in the company, valued at $5,843,255.16. The disclosure for this sale can be found here.

An institutional investor recently raised its position in China Biologic Products stock. Russell Frank Co increased its position in shares of China Biologic Products Inc. (NASDAQ:CBPO) by 69.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,104 shares of the biopharmaceutical company’s stock after buying an additional 5,764 shares during the period. Russell Frank Co owned about 0.05% of China Biologic Products worth $1,993,000 at the end of the most recent reporting period.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.